Welcure Drugs & Pharmaceuticals Share Price Today | Stock Price & Welcure Drugs & Pharmaceuticals Share Screener
As of October 5, 2026, the live Welcure Drugs & Pharmaceuticals share price (BSE: WELCURE) is ₹0.20, down 4.76% from the previous close, with shares trading between ₹0.20 and ₹0.22 in today's trading session, and a 52-week range of ₹0.20–₹0.71. Check WELCURE price range for the annual price range and momentum. Use the Welcure Drugs & Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Welcure Drugs & Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹366 and net income of ₹-5, with EBITDA of ₹-7, an operating margin of -2.0% and a profit margin of -1.4%.
Welcure Drugs & Pharmaceuticals Share Price Chart
Track the current stock price of Welcure Drugs & Pharmaceuticals with an interactive chart. Analyse WELCURE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Welcure Drugs & Pharmaceuticals stock quote in one place.
The quote of ₹0.20 sits between the 52-week low of ₹0.20 and the 52-week high of ₹0.71, and the latest session moved -4.76% from the previous close.
Welcure Drugs & Pharmaceuticals Company Profile - Fundamental Screener
Screen Welcure Drugs & Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for WELCURE shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE331C01025.
Company Details
Classification
Identifiers and Leadership
Welcure Drugs & Pharmaceuticals Balance Sheet Screener
Screen WELCURE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹510, up from ₹267 in 2025.
Latest statistics put total assets at ₹510 and shareholder funds at ₹97, with a leverage ratio of 1.19.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 510 | 267 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 358 | 182 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 123 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 97 | 103 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Capital | 124 | 112 | 13 | 13 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves & Surplus | -27 | -10 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 |
Welcure Drugs & Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Welcure Drugs & Pharmaceuticals income statement and profit fundamentals. Analyze WELCURE quarterly results. Welcure Drugs & Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-March, revenue was ₹366 and net profit was ₹-5, equal to earnings per unit of ₹-0.04, at an operating margin of -2%.
In that period expenses were ₹372, interest cost ₹0 and tax ₹0. The next period listed, 2025-March, shows revenue of ₹27 and net profit of ₹2.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||||
| Revenue | 366 | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 372 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Costs and Margins | ||||||||||||
| EBITDA | -7 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit % | -2.00% | 4.00% | 0.00% | 0.00% | 22.00% | 41.00% | -12.00% | 3.00% | -41.00% | 31.00% | 32.00% | 7.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | ||||||||||||
| Profit Before Tax | -5 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -5 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS | -0.04 | 0.36 | -0.13 | 0.08 | 0.02 | 0.05 | -0.01 | 0.00 | -0.02 | 0.02 | 0.07 | 0.00 |
Welcure Drugs & Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen WELCURE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹222.
Over the same period, investing activities provided ₹0 and financing activities provided ₹222.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -222 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing and Net Cash | ||||||||||
| Financing Activities | 222 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Welcure Drugs & Pharmaceuticals Shareholding Pattern Screener
See Welcure Drugs & Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Welcure Drugs & Pharmaceuticals promoter holding and ownership changes for WELCURE on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 0.00%, foreign institutions 0.00%, domestic institutions 0.00% and the public 95.63%, spread across 87,977 shareholders.
The shareholder count was 87,977 in 2026-Mar, compared with 32,366 in 2025-Mar.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 95.63% | 98.99% | 98.74% | 91.83% | 94.41% | 93.69% | 93.14% | 93.55% |
| Other Holding | 4.37% | 1.01% | 1.26% | 8.17% | 5.59% | 6.31% | 6.86% | 6.45% |
| Shareholder Count | 87,977 | 32,366 | 37,298 | 76,954 | 87,288 | 31,530 | 31,045 | 30,218 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Welcure Drugs & Pharmaceuticals. Welcure Drugs & Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
Welcure Drugs & Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Welcure Drugs & Pharmaceuticals stock. Check WELCURE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Welcure Drugs & Pharmaceuticals Market Events Screener - Corporate Actions
Get Welcure Drugs & Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Welcure Drugs & Pharmaceuticals stock events that may affect WELCURE share price, along with derivatives, futures and options activity and sector gainers.
11 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated May 29, 2026, with a record date of May 29, 2026.
It is followed by Quarterly Result Announcement dated February 12, 2026 and Quarterly Result Announcement dated November 13, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 3.57% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 9.09% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 10.91% |
| 2025-10-16 | 2025-10-16 | Bonus | 1:10 | 23.33% |
| 2025-10-16 | 2025-10-16 | Split | 1:10 | -35.09% |
| 2025-09-27 | 2025-09-27 | Annual General Meeting | NA | -31.25% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | 2.33% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 6.93% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -10.64% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 4.29% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 4.48% |
Welcure Drugs & Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen WELCURE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Welcure Drugs & Pharmaceuticals Company Announcements - News & Reports Screener
Screen WELCURE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated July 14, 2026.
The next most recent announcements are dated June 19, 2026 and June 19, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-07-14 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Ltd Held On Today I.E. Tuesday 14Th July 2026. | - |
| 2026-06-19 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-06-19 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Limited Held On Today I.E. Friday 19Th June 2026 | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-30 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-29 | Audited Standalone Financial Result For The Quarter And Year Ended 31St March 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of The Welcure Drugs And Pharmaceuticals Limited Held Today I.E. Friday 29Th May 2026 | - |
| 2026-05-22 | Board Meeting Intimation for Consideration And Approval Of The Audited Financial Results For The Quarter/Year Ended 31St March 2026 Along With Statement Of Assets And Liabilities And Cash Flow Statement For The Year Ended 31St March 2026. | - |
| 2026-04-23 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-03 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-12 | Unaudited Financial Results For The 3Rd Quarter Ended On 31St December 2025. | - |
| 2026-02-12 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Limited Held On Today I.E. Thursday 12Th February 2026 | - |
| 2026-02-07 | Board Meeting Intimation for Intimation Of Meeting Of The Board Of Directors To Be Held On Thursday February 12 2026. | - |
| 2026-01-05 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-24 | Closure of Trading Window | - |
| 2025-12-06 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs And Pharmaceuticals Limited Held Today I.E. Saturday December 06 2025 | - |
| 2025-12-05 | Postponement Of The Meeting Of The Rights Issue Committee Of Welcure Drugs And Pharmaceuticals Limited Which Was To Be Held Today I.E. Monday December 05 2025 | - |
| 2025-12-01 | Board Meeting Intimation for Intimation Of Rights Issue Committee Meeting To Be Held On 05Th December 2025 For Deciding Issue Price And Other Terms Of The Rights Issue | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹0.20, within a 52-week range of ₹0.20 to ₹0.71. The P/E ratio is -5.25 and the P/B ratio is 0.27, with earnings per unit of ₹-0.04. Market capitalisation stands at ₹27.24 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 12 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.